

Freedom of Information (Scotland) Act 2002

Date received	29/06/2022	Subject	Cancer treatments		
Passed to	Pharmacy	Date passed	04/07/2022	Respond by	20/07/2022
Category	Business	FOI number	2022-233		

Question/s to be answered

Please answer these questions relating to the usage of Dabrafenib + Trametinib in cancer treatment.

1. Over the previous 6 months, how many patients for the following diseases have been treated with a combination of Dabrafenib + Trametinib:
 - a. Metastatic Melanoma
 - b. Adjuvant Melanoma
 - c. BRAF mutated Lung Cancer

In accordance with FOISA s 17(1), NHS Shetland confirms that it does not hold the information requested.

Collation of this information would require a clinical audit of individual patient notes as NHS Shetland does not hold disease-specific information relating to medicines use.

In paragraph 46 of the Scottish Information Commissioner's briefing on FOISA s 17 (<https://www.itspublicknowledge.info/sites/default/files/2022-03/BriefingSection17Informationnoheld.pdf>) it is stated that "if collation of the information would require skill and complex judgement, the information is not held". For the reasons stated above, NHS Shetland considers that the review of patient notes and collation of the requested information would require skill and complex judgement and so issues this notice that the information requested is not held.